News Report

Coronavirus Update: After FabiFlu, Now Potential COVID-19 Drug Covifor and Cipremi To Hit The Market

While Glenmark Pharmaceuticals has launched favipiravir under the brand name FabiFlu for treatment of mild to moderate cases of Covid-19, Cipla and Hetero Labs have received approvals from the Drug Controller General of India to launch generic versions of Remdesivir under the brand names Cipremi and Covifor respectively. #FabiFlu #Covifor #Cipremi

Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.

Related posts